NCT02628613View on ClinicalTrials.gov

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Breast Cancer
Interventions
DRUG

Vinorelbine plus Epirubicin

Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations

DRUG

Paclitaxel plus Epirubicin

standard neoadjuvant chemotherapy

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02628613 - Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations | Biotech Hunter | Biotech Hunter